Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALCAINE vs NEVANAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis and thereby suppressing ocular inflammation and pain.
Ophthalmic anesthesia for procedures such as cataract extraction, tonometry, gonioscopy, and suture removal
Treatment of pain and inflammation associated with cataract surgery,Reduction of risk of macular edema following cataract surgery
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
One drop of 0.1% ophthalmic suspension instilled into the affected eye(s) three times daily.
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
The terminal elimination half-life of nepafenac is approximately 12.5 hours in plasma, while its active metabolite amfenac has a half-life of about 24 hours. This supports twice-daily dosing.
Hydrolyzed by plasma esterases.
Nepafenac is metabolized via ocular tissues to amfenac, the active metabolite. Systemic metabolism primarily involves hepatic conjugation and oxidation.
Renal excretion of parent drug and metabolites: <5% unchanged.
Nepafenac is extensively metabolized, primarily via hydrolysis to amfenac. Renal excretion accounts for approximately 85% of the administered dose, with about 13% excreted as unchanged nepafenac and amfenac in urine. Fecal elimination is minimal.
Minimal; <5% bound to plasma proteins.
Nepafenac is approximately 98% bound to plasma proteins, primarily albumin.
Not clinically meaningful due to rapid hydrolysis; Vd estimated <0.5 L/kg (low, consistent with high water solubility and rapid clearance).
The apparent volume of distribution (Vd/F) is approximately 0.6 L/kg (range 0.5-0.7 L/kg), suggesting distribution into total body water and some tissue binding.
Ophthalmic topical: negligible systemic absorption (minimal bioavailability); not applicable systemically.
Ophthalmic: Systemic bioavailability after topical ocular administration is very low (approximately 0.1-1% of the dose), but sufficient for local ocular effects. Oral bioavailability is not clinically relevant as drug is only used ophthalmically.
No dose adjustment required; negligible systemic absorption.
No dose adjustment required in renal impairment; systemic exposure is minimal due to topical administration.
No dose adjustment required; negligible systemic absorption.
No dose adjustment required in hepatic impairment; systemic exposure is minimal.
1 drop of 0.5% solution topically to the eye, repeated as needed; maximum 1 drop per dose in infants and young children to avoid systemic effects.
Safety and efficacy in pediatric patients have not been established; use is not recommended.
No specific adjustment; use lowest effective dose due to potential increased corneal sensitivity and delayed healing.
No specific dose adjustment; dosing is identical to standard adult dosing.
Not for injection or prolonged use; corneal toxicity with repeated or prolonged use.
No FDA black box warning.
Prolonged use may cause corneal epithelial damage and delay wound healing. Avoid contamination of the dropper tip.
Increased bleeding time due to antiplatelet effect,Delayed healing or corneal adverse events including keratitis and corneal perforation,Cross-sensitivity with aspirin or other NSAIDs,Use with caution in patients with bleeding diatheses or concurrent anticoagulants
Hypersensitivity to any component of the formulation.
Hypersensitivity to nepafenac or any component of the formulation,History of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs
None known.
No clinically significant food interactions have been identified with ophthalmic nevanac. Systemic absorption is minimal, so dietary restrictions are not required.
Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects at doses up to 0.5 mg/kg (SC). Potential fetal risk unlikely to exceed background risk. No known trimester-specific risks.
Nepafenac is an NSAID. First trimester: limited human data, but NSAIDs as a class are associated with increased risk of spontaneous abortion and cardiac defects. Second trimester: generally considered lower risk for teratogenicity, but avoid if possible. Third trimester: increased risk of premature closure of the ductus arteriosus, oligohydramnios, and fetal renal impairment. Ophthalmic use results in minimal systemic absorption, but theoretical risks remain. Use only if clearly needed.
Proparacaine is excreted into breast milk in unknown amounts, but due to minimal systemic absorption, the expected dose to infant is negligible. Manufacturer advises caution. No M/P ratio available.
No data on nepafenac in breast milk. Ophthalmic administration yields negligible systemic concentrations. M/P ratio not determined. Considered likely compatible with breastfeeding due to minimal absorption, but caution advised.
No dosing adjustment required for topical ophthalmic use due to negligible systemic absorption and lack of pharmacokinetic alterations in pregnancy.
No dose adjustments are typically required due to ophthalmic administration; systemic exposure is negligible. However, avoid use in third trimester unless potential benefit outweighs risk. No pharmacokinetic changes in pregnancy necessitate dose adjustment for topical ophthalmic formulation.
ALCAINE (proparacaine) is a topical ophthalmic anesthetic. Onset within 20 seconds, duration ~15 minutes. Do not dispense for home use due to risk of corneal toxicity with prolonged use. Use a sterile, single-dose vial to prevent contamination. Monitor for stinging or burning on instillation. Avoid in patients with sulfite allergy (contains sodium bisulfite).
Nevanac (nepafenac) is a nonsteroidal anti-inflammatory drug (NSAID) ophthalmic suspension indicated for pain and inflammation associated with cataract surgery. Its prodrug formulation enhances corneal penetration, with active metabolite amfenac inhibiting COX-1 and COX-2. Administer one drop three times daily starting 1 day prior to surgery, continuing on day of surgery and for 2 weeks postoperatively. Avoid concurrent use of other NSAIDs or corticosteroids to mitigate risk of corneal adverse events. Monitor for signs of corneal epithelial breakdown, especially in patients with compromised corneal innervation (e.g., diabetes, prior ocular surgery).
Temporary stinging or burning may occur upon application.,Do not touch the dropper tip to any surface to avoid contamination.,Do not use for more than instructed; prolonged use can damage the cornea.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Notify your doctor if you have a sulfite allergy.
Wash hands before and after instilling the drop.,Remove contact lenses before use and wait 10 minutes after administering before reinserting.,Do not touch the dropper tip to any surface to avoid contamination.,Apply one drop to the affected eye three times daily as directed, starting one day before cataract surgery.,Temporary blurred vision may occur; avoid driving or operating machinery until vision clears.,Notify your doctor if you experience eye pain, redness, sensitivity to light, or changes in vision.,Do not use other eye drops without consulting your doctor, especially other anti-inflammatory medications.,Store the bottle upright at room temperature, away from heat and light, and discard any unused suspension after the treatment period.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALCAINE vs NEVANAC, answered by our medical review team.
ALCAINE is a Local Anesthetic that works by Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.. NEVANAC is a NSAID Ophthalmic that works by Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis and thereby suppressing ocular inflammation and pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALCAINE and NEVANAC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALCAINE is: 1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.. The standard adult dose of NEVANAC is: One drop of 0.1% ophthalmic suspension instilled into the affected eye(s) three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALCAINE and NEVANAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALCAINE is classified as Category C. Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant wom. NEVANAC is classified as Category C. Nepafenac is an NSAID. First trimester: limited human data, but NSAIDs as a class are associated with increased risk of spontaneous abortion and cardiac defects. Second trimester: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.